Background: Thymidylate synthase (TS) has been associated with clinical outcome in disseminated colorectal cancer. However, many patients with lowTS expression still fail to respond to treatment. Therefore, we studied the cell cycle proteins, Rb, E2F2, Ki67, p21 and p53 and the apoptotic proteins, mcl-1. bax, bcl-xl, bcl-2, Fas receptor, Fas ligand, caspase-3, M30 and PARP as potential predictive factors.
Introduction
Colorectal cancer is one of the most common malignancies in Western countries. Systemic chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) is the most common treatment in advanced colorectal cancer, with a response rate of 23% [1] . In patients with non-resectable liver metastases, hepatic arterial infusion (HA1) of 5-FU is a valid alternative to systemic treatment. Response rates are about 41% [2] .
The target enzyme for 5-FU is thymidylate synthase (TS). TS catalyses the methylation of deoxyuridine-5'-monophosphate (dUMP) to deoxythymidine-5'-monophosphate (dTMP), with 5,10-methylene-tetrahydrofolate (CH 2 -THF) as limiting methyl donor. The active metabolite of 5-FU, 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) forms a ternary complex with TS and CH 2 -THF leading to TS inhibition. This complex formation is stimulated by LV [3, 4] .
In the past, it has been demonstrated that patients with low TS levels, have a better clinical outcome after i.v. or HAI of 5-FU than patients with high tumour TS levels [3, [5] [6] [7] [8] [9] . Nevertheless, a subset of patients with a lowTS expression failed to respond to treatment. Other factors, such as those involved in cell growth inhibition or programmed cell death, might therefore also predict for resistance to 5-FU treatment. Possible candidates are p53, p21, Rb and E2F, which are, among others, important for cell cycle regulation. Upon drug induced DNA damage, the tumour suppressor p53 activates p21 to initiate cell cycle arrest [10, 11] . Rb forms a complex with E2F1 and E2F2 inhibiting their transcriptional activity. After phosphorylation of Rb by specific kinases, E2F1 is released [12] resulting in the transcription of genes that activate cell cycle progression, such as TS [13] . Other possible predictive factors are the apoptosis regulators bax, bcl-2, bcl-xl, mcl-1, Fas receptor. Fas ligand and caspase-3. An excess of bax, which can be induced by p53 [14] , activates apoptosis whereas bcl-2. bcl-xl and mcl-1 protect cells against apoptosis [15, 16] . The death receptor, Fas, can be activated by Fas ligand resulting in activation of caspase-8 and -3 [17] . Caspase-3 can cleave functional proteins such as the DNA repair enzyme PARP [18] and structural proteins, like cytokeratin 18 in epithelial cells [19] , to induce apoptosis [20] . 
Chemicals
Primary antibodies were obtained from several sources; TS (R30) [22] from Dr Aherne (Sutton, UK), Rb (Rb-1) [23] from Novocastra (Newcastle, UK), M30 [24] from Boehringer Mannheim (Germany), PARP (C2-10) [25] from Pharmingen (San Diego, USA), Fas receptor (DX2) [26] , E2F2 and p2l (WAF-1) [27] from Oncogene (Cambridge, USA), caspase-3 (clone 19) [28] from Immunotech (Marseille, France), Fas hgand (clone 33) [29] from Transduction (Lexington, USA),p53 (t>01) [30] [31] [32] , Ki67 [31] , bcl-2 (clone 124) [32] , bcl-.xl [33] , ba.x [34] , and mcl-1 [35] from DAKO (Glostrup, Denmark). Biotinylated goat-anti-mouse immunoglobulines, normal goat serum and streptavidin-biotin conjugated horse radish peroxidase (sABC-HRP) were obtained from DAKO and biotinylated goat-anti-rabbit immunoglobulines from Vector Laboratories (Burlinghame, California, USA). Saponine, streptavidine, D-biotin, poly-L-lysine and di-amino-benzidine-HCL (DAB) were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht, The Netherlands) Unless otherwise specified, all other chemicals were of analytical grade and commercially available.
In this study, we determined whether the expression of cell cycle regulators and apoptotic factors in liver metastases of 31 colorectal cancer patients, is predictive for clinical outcome after 5-FU treatment. To get a good indication which factors might be important, the immunohistochemical staining of 15 proteins was evaluated before treatment, and was related to response to chemotherapy, time to tumour progression (TTP) and overall survival.
Patients and methods

Patients
Thirty-one patients with histologically proven liver metastases entered this study to be treated with HAI of 5-FU (Table 1 ). All patients. 16 men and 15 women with a median age of 54 years, had measurable metastases from which biopsy specimens were taken for cell cycle and apoptosis protein expression analysis using immunohistochemistry. Thereafter, 5-FU treatment was started Twenty-five patients received 5-FU via HAI. During laparotomy, an arterial access device (Port-aCath; Pharmacia Deltec. St. Paul, Minnesota) was implanted to allow HAI of 5-FU [21] . 5-FU (1000 mg/m 2 /d for 6 days) was administered as a continuous infusion using the Pharmacia Deltec CADD-1 pump. Treatment was usually initiated two to three weeks after implantation of the Port-a-Cath, and repeated every three weeks. Seven of these twenty-five patients also received post treatment with continuous infusion of5-FU and LVafter HAI treatment was stopped. Six patients who did not receive 5-FU via HAI due to complications with the Porta-Cath. were treated with a weekly i.v. bolus administration of 5-FU (500 mg/m 2 ) Ten of the 31 patients had received protracted FU based chemotherapy before metastases biopsy. Furthermore, a 5-FU bolus was given to 23 patients before biopsies were taken.
In all cases treatment was continued until disease progression or unacceptable toxicity was observed. Treatment results were evaluated every three to four months. Complete response (CR) was defined as the complete disappearance of the measurable metastasis on computed tomographic scan for a period of at least four weeks Partial response (PR) was defined as a reduction of the measurable metastasis by
Immunohistochemlcal staining
Biopsy specimens of liver metastasis obtained from colorectal cancer patients were immediately frozen in liquid nitrogen and subsequently stored at -80 °C. Frozen tissue sections (4 um) were mounted on poly-L-lysine (0.1%) coated slides and immunohistochemistry was performed as described previously [36] . Briefly, slides were fixed for 10 min with 100% acetone (forTS.pJi, Ki67, Fas, Fas hgand, M30, caspase-3 and bcl-2) or with 4% paraformaldehyde (for p2l, E2F2, Rb, bcl-xl. ba.x. mcl-1 and PARP). After blocking of endogenous peroxidase and biotin, slides were incubated for 1 hour with antibodies against TS (1:250), p53 (1:500), Ki67 (1:40), Fas receptor (1:25), Fas ligand (1:400), caspase-3 (1:500) and bcl-2 (1:50) and overnight with Rb (1:40), PARP (1: 500), E2F2 (1 : 100), p21 (1: 40), bcl-.xl. ba.x and mcl-1 (1: 100). Primary antibodies were detected by anti-mouse or anti-rabbit biotinylated secondary antibodies for 30 min. Staining was developed by incubation of sections with sABC-HRP (1:200; I hour) and visualised by DAB (0.5 mg/ml) with 0 025% H 2 O 2 for 3 min For Fas ligand, caspase-3 and E2F2, an additional amplification step with CARD (catalyzed reporter deposition) enhancement kit (DAKO) was needed [37] All slides were counterstained with hematoxylin. Negative controls were performed for each sample by omitting the primary antibody.
Immunohistochemieal scoring
A pathologist (EB) and two investigators (DFand HB) independently evaluated slides for each antibody without knowledge of the clinical history and outcome. As published before, p53 [38, 39] , p21, Ki67, Rb [38] and bcl-2 [39, 40] were evaluated by scoring the percentage of positive tumour cells in four categories (<25%, 26%-50%, 5l%-75% and 76%-100%). ForTS [7, 41] , Rb, Fas ligand [29, 42] , PARP, E2F2 and caspase-3 the intensity of the staining was taken into account because these proteins were expressed in almost all tumour cells. The intensity was divided in three categories; low, intermediate or high. Ba.x [43] , mcl-1 and bcl-.xl [43] were evaluated by scoring the pattern of their expression: diffuse or peri-nuclear punctation. Fas receptor was only evaluated as negative or positive. In all cases the inter-observer variability was < 10%.
Positive controls included normal colon mucosa (for Fas receptor, Fas ligand, p21, Rb, PARP, Ki67 and E2F2), tonsils (for Fas ligand, bcl-2. ba.x and caspase-3), tumour cells with high protein expression (for all tested antibodies) and the internal controls in the samples such as normal liver (for Fas receptor, Rb and caspase-3 and lymphocytes (for bcl-2).
Quantification of the M30 immunostaining
The percentage of M30 positive tumour cells was quantified using a commercially available interactive video-overlay-based measuring system (Q-PRODIT, Leica, Cambridge, UK). The microscopic image was recorded by a CCD camera and displayed on a monitor. Two hundred fields of vision were systematically randomly selected using an automatic scanning stage controlled by a computer [44, 45] , In these fields, a total of at least 200 neoplastic cells, as determined by morphology, were sampled with a Weibel four-point test grid and scored positive or negative for M30 staining. All data were expressed as a percentage of positive cells counted in relation to the total number of cells counted. A 40 x objective was used, giving a final magnification of 1200 x
Statistical methods
The percentage and intensity of immunoreactive tumour cells for the cell cycle and apoptosis proteins were dichotomised into two groups (Tables 2 and 3 ). The cut-off points (or P 53 [40] , bcl-2 [40] and TS [41] expression were chosen based upon previously published reports. For Rb, Ki67, p2l and M30 cut-off points were chosen to best separate the patients, whereas for Fas ligand, E2F2, caspase-3 and PARP cut-off points were based on intensity, low or intermediate and high expression. Statistical differences between patients with complete or partial response and those with stable or progressive disease were determined using the non-parametric Mann-Whitney U ranking test (two-tailed) Survival rates were estimated by the Kaplan-Meier method and tested for significance by the log-rank test, while multivanate comparisons were conducted using the Cox regression analysis. TTP was also estimated for significance by the log rank test. A /"-value of <0.05 was considered significant. All statistical procedures were carried out with SPSS 9.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Clinical outcome
After 5-FU treatment 1 patient (3%) had a complete remission, 15 (48%) had a partial response, 9 (29%) had a stable disease and in 6 (19%) cases tumour progression was observed. Median TTP of the 31 patients was 29 weeks with a 95% confidence interval (CI) ranging from 21.4 to 36.6 weeks. Twenty-nine patients died from causes related to cancer whereas one patient was still alive at the time of survival evaluation. One patient could not be evaluated for survival. The median survival time was 49 weeks (CI: 26.5-71.5 weeks) ( Table 1) .
Cell cycle and apoptosis protein expression in liver metastases
The expression of cell cycle and apoptosis dependent markers (Tables 2 and 3 ) was investigated in frozen sections of liver metastases from 31 colorectal cancer patients. In some metastases samples protein expression was not evaluable due to bad sample quality. In all liver metastases tumour cells were found which were positive for TS, Rb-1, Ki67, M30, bax, bcl-xl, mcl-1. caspase-3 and Fas ligand, whereas completely negative liver 
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Patients were treated with either hepatic arterial or I.V. infusion of 5-FU. Median TTP and median survival after treatment are given with SE in weeks. Significant differences (P < 0.05) between liver metaslases of patients with high and low apoptotic expression are indicated with * and are independent of age, sex and pre-treatment. metastases were also seen for the other proteins <j>53, p21, E2F2, PARP, Fas receptor and bcl-2). Only 13 and 7% of liver metastases were positive (>25% of positive tumour cells) for p21 (Table 3) and bcl-2 (Table 2) , respectively, whereas 80% of the metastases were positive for p53 (Table 3) . Other proteins showed a more equal distribution among metastases with a high or low protein expression (Tables 2 and 3) .
Apoptosis protein expression and clinical outcome
The expression of proteins involved in apoptosis was not significantly correlated with TTP and overall survival. Patients with a low expression of Fas receptor, Fas ligand, caspase-3, M30, PARP, bax. bcl-2. bcl-xl and mcl-1 had a similar median TTP and survival time compared to patients with high expression of these proteins (P > 0.05) ( Table 2) . A significant survival benefit was found when only patients were taken into account that received 5-FU via HAI (results not shown). Patients with M30 expression lower than 20% lived longer compared to patients that had a M30 expression above the cut-off point (P = 0.05, log-rank test). No significance could be found by multivariate analysis. Expression of the anti-apoptotic protein mcl-1 correlated with response following infusion of 5-FU. Patients with a peri-nuclear mcl-l expression showed a response rate of 90%, whereas those with a diffuse expression had a response rate of 35% (P = 0.041) ( Table 2) . Furthermore, a trend was observed for the expression of bax. Patients with metastases with a diffuse bax expression responded worse to treatment (45%) compared to those with perinuclear bax expression (75%; P = 0.063) ( Table 2 ). The other proteins involved in apoptosis did not correlate with response to 5-FU treatment.
Cell cycle protein expression related to clinical outcome
Clinical outcome and TS expression correlated when patients were evaluated that received 5-FU via HAI only. Although several patients received 5-FU treatment before taking tumour biopsy specimens, this did not affect the relation between TS expression and clinical outcome. Statistical analyses would indicate a possible effect of treatment on TS expression. A longer survival (P = 0.025, log-rank) ( Figure 1 ) and increased TTP (P = 0.044) were found in patients with a low TS expression compared to those with a high expression of shown. The probability of surviving after 5-FU infusion via HAI only, for patients with high expression of TS was significantly lower than the probability for patients with lowTS expression (P = 0.025, log-rank test). Kaplan-Meier curves for the probability of survival of the 29 patients with liver metastases that were evaluated for p53 expression are shown. The probability of surviving for patients with high expression of p53 was significantly higher than the probability for patients with low p53 expression {P = 0.027. log-rank test) TS. However, when all patients were evaluated, expression of the target enzyme TS did not correlate with response to 5-FU treatment, TTP or survival (P > 0.05; Table 3 ).
The expression of the tumour suppressor gene p53 correlated with TTP (Table 3) . Tumour progression was detected later in patients when p53 expression was above the cut-off point of 25% compared to those that expressed p53 expression below the cut-off (30 vs. 22 weeks, respectively; P -0.040, log-rank test). In addition, overall survival was longer in patients with high p53 expression. A survival benefit of 40 weeks was found comparing patients with a high p53 expression with those with a low p53 expression (P = 0.027, log-rank test) (Figure 2 ). The expression of Rb was also correlated with survival benefit. Patients with a high intensity of Rb survived longer after 5-FU treatment when compared to those with a low or intermediate expression of Rb; 79 vs. 44 weeks (P -0.030, log-rank test) (Figure 3 ). Significant differences could also significantly correlated with survival, independent of the age and sex of the patients and whether the patients had prior treatment or not. In contrast to survival, Rb and p53 expression were not associated with response (Table 3) . For the other cell cycle proteins, Ki67, E2F2 and p2l, no association with clinical outcome was found ( Table 4) . The median survival time seemed to be longer for patients with intermediate/high tumour expression of either Ki67, E2F2 or p2l compared to the low expressors, but none of these differences were significantly different (P > O.I). The median TTP, ranging from 28 to 42 weeks was independent of the Ki67, E2F2 and p2l expression. Furthermore, there was no significant difference in response rates between the high or low Ki67 and E2F2 expressing groups. Only for p2l, a trend was observed (P = 0.07). All 4 patients with a high metastatic expression of p2l responded to 5-FU treatment whereas only 45% of the 26 patients with low p2l expression responded (Table 3) .
Discussion
The data in this study demonstrate that in addition to TS, the expression of Rb, incl-1 and p53 in liver metastases correlate with clinical outcome of advanced colorectal cancer patients treated with 5-FU.
Results published previously [8, 46] show that lowTS expression was associated with survival benefit after chemotherapy with 5-FU. 5-FU mediated TS inhibition will be more effective in patients with lowTS expression, which can explain why these patients respond better to 5-FU treatment compared to those with high TS levels. However, significant clinical improvement in our study was only found in patients that received 5-FU via HA1 and not when all patients including those that only received systemic 5-FU treatment, were taken into account. The lower response rate in systemically treated patients might have influenced the correlation.
Some patients with lowTS levels still do not respond and therefore proteins involved in cell cycle regulation were investigated as possible predictive factors. Rb, p53 and possibly p21 were associated with clinical outcome. Patients with low Rb or \ow p53 expression had a shorter median TTP and overall survival time compared to those with a high Rb or high p53 expression in the metastases. Low expression of Rb in metastases might be caused by a deregulation of cell cycle mechanisms and is probably not due to the loss or inactivation of the Rb gene, which occurs infrequent in primary colorectal carcinomas [47] . Low Rb expression will result in an increase of free E2F1 and E2F2 proteins [12] , which can stimulate tumour growth, and thereby reducing survival. In line with this finding was the trend that patients with high p21 expression, possibly inducing cell cycle arrest, responded better to 5-FU treatment compared to patients with low p21 expression.
Controversial data have been published concerning the role of p53 in response to 5-FU therapy [48] . Overexpression of p53, which is associated with p53 mutations in 69% of colorectal carcinomas [49] , was correlated with poor survival after treatment with fluorodeoxyuridine via HAI [50] . However, two other groups could not find a relation between p53 expression and survival after i.v. 5-FU treatment [51, 52] . Differences between the various studies can be caused by the different antibodies that were used, and by the way of 5-FU administration. Furthermore, it is possible that high expression of p53 is not only associated with mutations in p53 but also with activated wild-type p53 leading to cell cycle arrest [10] and improved clinical outcome. Since the expression of both p53 and Rb in liver metastases of patients may be related to favourable tumour growth characteristics, it is possible iha.i p53 and Rb do not select patients refractory to 5-FU but only those with a more favourable prognosis.
Proteins involved in the regulation of apoptosis have been studied in colon carcinoma cell lines as possible treatment resistance factors [53, 54] but in clinical studies information is limited. The expression of bcl-2 was not related to response or overall survival in patients with colorectal carcinomas receiving 5-FU based chemotherapy [55] . Similar results with bcl-2 were found in our study. Only the anti-apoptotic protein mcl-I, which can inhibit apoptosis at the mitochondria, was correlated with clinical outcome. A peri-nuclear expression, which might indicate that there is specific expression of mcl-I at the mitochondria and thus inhibition of apoptosis, was associated with response. In line with this is the obser-vation that a low percentage of apoptosis as measured by M30 staining was related to survival benefit. Liver metastases with a high rate of apoptosis probably proliferate very fast and therefore the overall survival of patients might be decreased.
In summary, this study suggests that p53, Rb and probably mcl-l could be used in the future as possible additional markers for selection of advanced colorectal cancer patients to improve the results of 5-FU treatment. To give a definitive answer to whether these proteins are to be used as prognostic or predictive factors for routine use, prospective clinical studies must be conducted in larger patient groups.
